VEP estimation of visual acuity: a systematic review.
VEP estimation of visual acuity: a systematic review.
复制标题
视觉诱发电位评估视力的系统评价
DOI：
10.1007/s10633-020-09770-3
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Thompson DA
中科院分区：
文献类型：
--
作者：
Hamilton R;Bach M;Heinrich SP;Hoffmann MB;Odom JV;McCulloch DL;Thompson DA
视觉诱发电位（VEP）可用于通过空间频率（SF）极限来测量视觉分辨率，作为视觉敏锐度的客观估计。本系统综述的目的是整理健康和疾病人群中VEP SF限值的描述，并评估VEP SF限值如何准确和精确地反映视力。方案方法遵循PRISMA声明。使用“VEP”和“敏锐度”及相关术语以及手动检索检索多个数据库：审查标题、摘要或全文的合格性。提取的数据包括VEP SF限值、刺激方案、VEP记录和分析技术以及与视力正常的健康成人（通常为发育中的婴儿和儿童）、人工视力下降的健康成人和患有眼科或神经系统疾病的患者的行为敏锐度的对应关系。共纳入155项研究。常用的刺激，记录和分析技术进行了总结。平均健康成人VEP SF限值从15到40 cpd不等，取决于刺激，记录和分析技术，并且通常但不总是比用相同刺激或临床敏锐度测试测量的行为敏锐度差。VEP SF限值和行为敏锐度之间的差异是可变的，并且强烈依赖于VEP刺激和敏锐度测试的选择。VEP SF限制迅速成熟，从出生后第一个月末的1.5 - 9 cpd到8-12个月的12-20 cpd，缓慢改善到3-5年的20-40 cpd。VEP SF限值比最年幼、通常发育中的婴儿的行为阈值好得多。这种差异随着年龄的增长而减小，在1至2岁之间达到相等;从大约3-5岁开始，行为敏锐度优于VEP SF限值，与成人一样。健康、人工模糊的成人在广泛的视力范围内的行为视力略好于VEP SF限值，而患有导致视力下降的异质性眼科或神经病理的成人表现出更广泛且不太一致的关系。对于屈光不正、眼介质混浊或主要影响视网膜的病理，VEP SF限值和行为敏锐度在广泛的敏锐度范围内具有相当一致的关系。对于主要是黄斑、视神经或弱视等神经系统疾病来说，这种关系不太一致或密切。非器质性视力丧失患者的VEP SF限值几乎总是正常的。VEP SF限值作为客观敏锐度估计器具有很大的实用性，特别是在言语前儿童或任何年龄的运动或学习障碍患者中，这些患者无法可靠地测量行为敏锐度。其诊断能力在很大程度上取决于足够的，年龄分层，参考数据，年龄分层的经验校准与行为敏锐度，并在其他电生理和临床结果的光解释。未来的发展可能包括更快，更客观和更强大的技术，如实时，自适应控制。 PROSPERO系统性综述国际前瞻性注册库（https：//www.crd.york.ac.uk/PROSPERO/），注册号CRD 42018085666。
Visual evoked potentials (VEPs) can be used to measure visual resolution via a spatial frequency (SF) limit as an objective estimate of visual acuity. The aim of this systematic review is to collate descriptions of the VEP SF limit in humans, healthy and disordered, and to assess how accurately and precisely VEP SF limits reflect visual acuity. The protocol methodology followed the PRISMA statement. Multiple databases were searched using “VEP” and “acuity” and associated terms, plus hand search: titles, abstracts or full text were reviewed for eligibility. Data extracted included VEP SF limits, stimulus protocols, VEP recording and analysis techniques and correspondence with behavioural acuity for normally sighted healthy adults, typically developing infants and children, healthy adults with artificially degraded vision and patients with ophthalmic or neurological conditions. A total of 155 studies are included. Commonly used stimulus, recording and analysis techniques are summarised. Average healthy adult VEP SF limits vary from 15 to 40 cpd, depend on stimulus, recording and analysis techniques and are often, but not always, poorer than behavioural acuity measured either psychophysically with an identical stimulus or with a clinical acuity test. The difference between VEP SF limit and behavioural acuity is variable and strongly dependent on the VEP stimulus and choice of acuity test. VEP SF limits mature rapidly, from 1.5 to 9 cpd by the end of the first month of life to 12–20 cpd by 8–12 months, with slower improvement to 20–40 cpd by 3–5 years. VEP SF limits are much better than behavioural thresholds in the youngest, typically developing infants. This difference lessens with age and reaches equivalence between 1 and 2 years; from around 3–5 years, behavioural acuity is better than the VEP SF limit, as for adults. Healthy, artificially blurred adults had slightly better behavioural acuity than VEP SF limits across a wide range of acuities, while adults with heterogeneous ophthalmic or neurological pathologies causing reduced acuity showed a much wider and less consistent relationship. For refractive error, ocular media opacity or pathology primarily affecting the retina, VEP SF limits and behavioural acuity had a fairly consistent relationship across a wide range of acuity. This relationship was much less consistent or close for primarily macular, optic nerve or neurological conditions such as amblyopia. VEP SF limits were almost always normal in patients with non-organic visual acuity loss. The VEP SF limit has great utility as an objective acuity estimator, especially in pre-verbal children or patients of any age with motor or learning impairments which prevent reliable measurement of behavioural acuity. Its diagnostic power depends heavily on adequate, age-stratified, reference data, age-stratified empirical calibration with behavioural acuity, and interpretation in the light of other electrophysiological and clinical findings. Future developments could encompass faster, more objective and robust techniques such as real-time, adaptive control. International prospective register of systematic reviews PROSPERO (https://www.crd.york.ac.uk/PROSPERO/), registration number CRD42018085666.
登录
查看更多内容
影响因子：
3.6
作者：
Birch, EE;Hoffman, DR;Prestidge, C
通讯作者：
Prestidge, C
影响因子：
3.6
作者：
Auestad, N;Montalto, MB;Hartmann, EE
通讯作者：
Hartmann, EE
影响因子：
56.9
作者：
BODISWOLLNER, I;ATKIN, A;WOLKSTEIN, M
通讯作者：
WOLKSTEIN, M
影响因子：
4.1
作者：
Bach, M.;Maurer, J. P.;Wolf, M. E.
通讯作者：
Wolf, M. E.
影响因子：
1.4
作者：
Bach, Michael;Heinrich, Sven P.
通讯作者：
Heinrich, Sven P.